Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Controlling lipid levels in diabetes.

¹University of Helsinki, Department of Medicine, Finland.

Acta Diabetologica

|September 12, 2002

Summary

Patients with type 2 diabetes have higher risks of coronary heart disease (CHD). Statins effectively lower LDL cholesterol and triglycerides, reducing CHD events in diabetic patients with dyslipidaemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetically determined increase in apolipoprotein C-III (APOC3 gain-of-function) delays very low-density lipoprotein clearance in humans.

Atherosclerosis·2025

Same author

Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twins.

Obesity (Silver Spring, Md.)·2013

Same author

Response letter to D. Singh-franco et al.

Diabetes, obesity & metabolism·2012

Same author

Heritability and familiality of type 2 diabetes and related quantitative traits in the Botnia Study.

Diabetologia·2011

Same author

Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance.

Diabetologia·2007

Same author

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

Diabetologia·2007

Area of Science:

Cardiology
Endocrinology
Pharmacology

Background:

Type 2 diabetes significantly increases coronary heart disease (CHD) risk.
Diabetic dyslipidaemia, characterized by high triglycerides, low HDL, and small, dense LDL, is a key CHD risk factor.
Standard diabetes management often fails to fully correct these lipid abnormalities.

Purpose of the Study:

To review the role of statins in managing diabetic dyslipidaemia.
To highlight the efficacy of statins in reducing CHD events in diabetic patients.

Main Methods:

Review of current treatment guidelines and recent clinical trial evidence.
Focus on statin therapy for lipid management in type 2 diabetes.

Main Results:

Statins are effective and well-tolerated for lowering LDL cholesterol without negatively impacting glycaemic control.
Emerging evidence supports statins for treating elevated triglycerides.
Lipid-lowering therapy with statins significantly reduces CHD events in patients with diabetic dyslipidaemia.

Conclusions:

Statins are a crucial therapeutic intervention for diabetic dyslipidaemia.
Statin therapy offers significant cardiovascular protection for patients with type 2 diabetes and dyslipidaemia.

Related Experiment Videos